FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016647946> ?p ?o ?g. }

• W2016647946 endingPage "30159" @default.
• W2016647946 startingPage "30154" @default.
• W2016647946 abstract "Lysophosphatidylcholine (lyso-PC) is a major component of atherogenic lipids that stimulate vascular smooth muscle cell (SMC) proliferation. Because cationic amino acids are metabolized to growth-stimulatory polyamines, we examined whether lyso-PC regulates the transcellular transport and metabolism of cationic amino acids by vascular SMC. Treatment of SMC with lyso-PC initially (0–2 h) decreased cationic amino acid uptake, whereas longer exposures (6–24 h) progressively increased transport. Kinetic studies indicated that lyso-PC-induced inhibition was associated with a decrease in affinity for cationic amino acids, but the stimulation was mediated by an increase in transport capacity. Lyso-PC strongly induced the expression of cationic amino acid transporter-2 mRNA while modestly elevating the level of cationic amino acid transporter-1 mRNA. In addition, lyso-PC stimulated intracellular cationic amino acid metabolism by inducing ornithine decarboxylase activity and mRNA expression and also by inducing arginase activity in vascular SMC. In contrast, lyso-PC inhibited the catabolism ofl-arginine to nitric oxide by blocking inducible nitric oxide synthase expression. Lyso-PC increased markedly the capacity of SMC to generate putrescine, a polyamine, from extracellularl-ornithine and l-arginine. The lyso-PC-mediated increase in the production of putrescine was reversed by N G-methyl-l-arginine, a competitive inhibitor of cationic amino acid transport, or by α-difluoromethylornithine, an ornithine decarboxylase inhibitor. The formation of putrescine from l-arginine was also prevented by arginase inhibitorN G-hydroxy-l-arginine. These results demonstrate that lyso-PC stimulates polyamine synthesis in vascular SMC by inducing the expression of the genes that regulate both the transport and metabolism of cationic amino acids. The actions of lyso-PC in stimulating cationic amino acid uptake and directing their metabolism to growth-stimulatory polyamines while simultaneously inhibiting the synthesis of antiproliferative NO, may contribute to lyso-PC-induced SMC proliferation and atherosclerotic lesion formation. Lysophosphatidylcholine (lyso-PC) is a major component of atherogenic lipids that stimulate vascular smooth muscle cell (SMC) proliferation. Because cationic amino acids are metabolized to growth-stimulatory polyamines, we examined whether lyso-PC regulates the transcellular transport and metabolism of cationic amino acids by vascular SMC. Treatment of SMC with lyso-PC initially (0–2 h) decreased cationic amino acid uptake, whereas longer exposures (6–24 h) progressively increased transport. Kinetic studies indicated that lyso-PC-induced inhibition was associated with a decrease in affinity for cationic amino acids, but the stimulation was mediated by an increase in transport capacity. Lyso-PC strongly induced the expression of cationic amino acid transporter-2 mRNA while modestly elevating the level of cationic amino acid transporter-1 mRNA. In addition, lyso-PC stimulated intracellular cationic amino acid metabolism by inducing ornithine decarboxylase activity and mRNA expression and also by inducing arginase activity in vascular SMC. In contrast, lyso-PC inhibited the catabolism ofl-arginine to nitric oxide by blocking inducible nitric oxide synthase expression. Lyso-PC increased markedly the capacity of SMC to generate putrescine, a polyamine, from extracellularl-ornithine and l-arginine. The lyso-PC-mediated increase in the production of putrescine was reversed by N G-methyl-l-arginine, a competitive inhibitor of cationic amino acid transport, or by α-difluoromethylornithine, an ornithine decarboxylase inhibitor. The formation of putrescine from l-arginine was also prevented by arginase inhibitorN G-hydroxy-l-arginine. These results demonstrate that lyso-PC stimulates polyamine synthesis in vascular SMC by inducing the expression of the genes that regulate both the transport and metabolism of cationic amino acids. The actions of lyso-PC in stimulating cationic amino acid uptake and directing their metabolism to growth-stimulatory polyamines while simultaneously inhibiting the synthesis of antiproliferative NO, may contribute to lyso-PC-induced SMC proliferation and atherosclerotic lesion formation. Lyso-PC 1The abbreviations used are: lyso-PC, 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine; SMC, smooth muscle cell(s); PDGF, platelet-derived growth factor; ODC, ornithine decarboxylase; CAT, cationic amino acid transporter; (i)NOS, (inducible) nitric oxide synthase; Tes,N-tris(hydroxylmethyl)methyl-2-aminoethanesulfonic acid; PC, phosphatidylcholine; l-NOHA,N G-hydroxy-l-arginine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; DFMO, α-difluoromethylornithine; MTT, 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; kb, kilobase(s). 1The abbreviations used are: lyso-PC, 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine; SMC, smooth muscle cell(s); PDGF, platelet-derived growth factor; ODC, ornithine decarboxylase; CAT, cationic amino acid transporter; (i)NOS, (inducible) nitric oxide synthase; Tes,N-tris(hydroxylmethyl)methyl-2-aminoethanesulfonic acid; PC, phosphatidylcholine; l-NOHA,N G-hydroxy-l-arginine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; DFMO, α-difluoromethylornithine; MTT, 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; kb, kilobase(s). is a major component of atherogenic lipoproteins and a product of phospholipase A2 which accumulates in atherosclerotic and inflammatory lesions of blood vessels (1Steinberg D. Parthasarathy S Carew T.E. Khoo J.C. N. Engl. J. Med. 1989; 320: 915-924Crossref PubMed Google Scholar, 2Witzum J.L. Steinberg D. J. Clin. Invest. 1991; 88: 1785-1792Crossref PubMed Scopus (2468) Google Scholar, 3Portman O.W. Alexander M. J. Lipid Res. 1969; 10: 158-165Abstract Full Text PDF PubMed Google Scholar). This polar phospholipid has multiple atherogenic effects. It stimulates macrophage proliferation and plays a critical role in foam cell formation (4Sakai M. Miyazaki A. Hakamata H. Sasaki T. Yui S. Yamazaki M. Shichiri M. Horiuchi S. J. Biol. Chem. 1994; 269: 31430-31435Abstract Full Text PDF PubMed Google Scholar). Lyso-PC also induces chemotaxis of leukocytes and activates endothelial expression of leukocyte adhesion molecules, resulting in the recruitment of leukocytes into the arterial intima (5Quinn M.T. Parthasarathy S. Steinberg D. Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 2805-2809Crossref PubMed Scopus (583) Google Scholar, 6Kume N. Cybulsky M.I. Gimbrone Jr., M.A. J. Clin. Invest. 1992; 90: 1138-1144Crossref PubMed Scopus (723) Google Scholar). In addition, lyso-PC promotes intimal thickening of blood vessels by stimulating SMC proliferation. Lyso-PC induces gene expression of potent SMC growth factors such as PDGF and heparin-binding epidermal growth factor-like protein in vascular cells and directly stimulates SMC proliferation (7Kume N. Gimbrone Jr., M.A. J. Clin. Invest. 1994; 93: 907-911Crossref PubMed Scopus (298) Google Scholar, 8Chai Y.-C. Howe P.H. DiCorleto P.E. Chisolm G.M. J. Biol. Chem. 1996; 271: 17791-17797Abstract Full Text Full Text PDF PubMed Scopus (138) Google Scholar, 9Stiko A. Regnstrom J. Shah P.K. Cercek B. Nilsson J. Arterioscler. Thromb. Vasc. Biol. 1996; 16: 194-200Crossref PubMed Scopus (78) Google Scholar, 10Chen Y. Morimoto S. Kitano S. Koh E. Fukuo K. Jiang B. Chen S. Yasuda O. Hirotani A. Ogihara T. Atherosclerosis. 1995; 112: 69-76Abstract Full Text PDF PubMed Scopus (68) Google Scholar). However, the mechanism by which lyso-PC induces SMC growth is not known. Recent studies indicate that the synthesis of polyamines plays an integral role in the mitogenic response of vascular SMC. SMC proliferation is preceded by increases in cellular polyamine content and inhibition of polyamine formation prevents cell growth (11Thyberg J. Fredholm B.B. Exp. Cell Res. 1987; 170: 160-169Crossref PubMed Scopus (46) Google Scholar, 12Nishida K. Abiko T. Ishihara M. Tomikawa M. Atherosclerosis. 1990; 83: 119-125Abstract Full Text PDF PubMed Scopus (24) Google Scholar, 13Durante W. Liao L. Iftikhar I. Cheng K. Shafer A.I. J. Biol. Chem. 1996; 271: 11838-11843Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). Furthermore, the exogenous addition of polyamines to SMC stimulates DNA synthesis (11Thyberg J. Fredholm B.B. Exp. Cell Res. 1987; 170: 160-169Crossref PubMed Scopus (46) Google Scholar). The polyamines putrescine, spermidine, and spermine are naturally occurring polycations found in all mammalian cells. Putrescine is generated from the basic amino acid l-ornithine via a decarboxylation reaction catalyzed by the enzyme ODC, whereas spermidine and spermine are synthesized from putrescine through the sequential addition of a propylamine moiety fromS-adenosylmethionine (14Tabor C.W. Tabor H. Annu. Rev. Biochem. 1984; 53: 749-790Crossref PubMed Scopus (3228) Google Scholar). Induction of ODC activity and polyamine synthesis is one of the earliest biochemical events associated with cell growth (14Tabor C.W. Tabor H. Annu. Rev. Biochem. 1984; 53: 749-790Crossref PubMed Scopus (3228) Google Scholar, 15Pegg A.E. Cancer Res. 1988; 48: 759-774PubMed Google Scholar). Both arterial injury-induced and PDGF-mediated SMC proliferation are associated with a striking increase in ODC activity (11Thyberg J. Fredholm B.B. Exp. Cell Res. 1987; 170: 160-169Crossref PubMed Scopus (46) Google Scholar, 13Durante W. Liao L. Iftikhar I. Cheng K. Shafer A.I. J. Biol. Chem. 1996; 271: 11838-11843Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 16Majesky M.W. Schwartz S.M. Clowes M.M. Clowes A.W. Circ. Res. 1987; 61: 296-300Crossref PubMed Scopus (152) Google Scholar). Moreover, the inhibition of ODC activity inhibits both arterial injury- and PDGF-mediated SMC proliferation, indicating that ODC activity is essential for SMC growth (11Thyberg J. Fredholm B.B. Exp. Cell Res. 1987; 170: 160-169Crossref PubMed Scopus (46) Google Scholar, 13Durante W. Liao L. Iftikhar I. Cheng K. Shafer A.I. J. Biol. Chem. 1996; 271: 11838-11843Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar,17Endean E.D. Kispert J.F. Martin K.W. O'Connor W. J. Surg. Res. 1991; 50: 634-637Abstract Full Text PDF PubMed Scopus (17) Google Scholar). Although ODC activity is often believed to be rate-limiting in the polyamine biosynthetic pathway, the availability ofl-ornithine also plays a crucial role in regulating polyamine synthesis. Previous studies demonstrate that the steady-state level of l-ornithine markedly influences polyamine formation and DNA synthesis in neoplastic cells (18Wu V.S. Byus C.V. Biochim. Biophys. Acta. 1984; 804: 89-99Crossref PubMed Scopus (15) Google Scholar, 19Gonzalez G.G. Byus C.V. Cancer Res. 1991; 51: 2932-2939PubMed Google Scholar). More recently, we have shown that PDGF-induced polyamine synthesis and vascular SMC mitogenesis are dependent on the transcellular transport of l-ornithine (13Durante W. Liao L. Iftikhar I. Cheng K. Shafer A.I. J. Biol. Chem. 1996; 271: 11838-11843Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). The transport of cationic (basic) amino acids, such as l-ornithine andl-arginine, by vascular SMC is mediated by the system y+ carrier (20Low B.C. Ross I.K. Grigor M.R. J. Cell. Physiol. 1993; 156: 626-634Crossref PubMed Scopus (23) Google Scholar, 21Durante W. Liao L. Schafer A.I. Am. J. Physiol. 1995; 268: H1158-H1164PubMed Google Scholar). This particular transport system is characterized by its recognition of basic amino acids with high affinity, its Na+-independence, and the ability of substrate on the opposite (trans) side of the membrane to increase transport activity (22White M.F. Biochim. Biophys. Acta. 1985; 822: 355-374Crossref PubMed Scopus (239) Google Scholar). Recently, the genes encoding the proteins responsible for the activity of the system y+carrier have been cloned and designated as CAT-1, CAT-2, and CAT-2A (23Albritton L.M. Tseng L. Scadden D. Cunningham J.M. Cell. 1989; 57 (634): 659Abstract Full Text PDF PubMed Scopus (553) Google Scholar, 24MacLeod C.L. Finley K.D. Kakuda D.K. Kozak D.K. Wilkinson M.F. Mol. Cell. Biol. 1990; 10: 3663-3674Crossref PubMed Scopus (80) Google Scholar, 25Closs E.I. Lyons C.R. Kelly C. Cunningham J.M. J. Biol. Chem. 1993; 268: 20796-20800Abstract Full Text PDF PubMed Google Scholar, 26Closs E.I. Albritton L.M. Kim J.W. Cunningham J.M. J. Biol. Chem. 1993; 268: 7538-7544Abstract Full Text PDF PubMed Google Scholar). Both CAT-1 and CAT-2 are low capacity transporters that have a high affinity (K m ≈ 100 μm) for cationic amino acids. In contrast, CAT-2A is an alternate splice variant of CAT-2 which possesses low affinity but high transport capacity (26Closs E.I. Albritton L.M. Kim J.W. Cunningham J.M. J. Biol. Chem. 1993; 268: 7538-7544Abstract Full Text PDF PubMed Google Scholar). In a previous study we found that vascular SMC express mRNA for both of the high affinity transporters, CAT-1 and CAT-2, but do not express message for CAT-2A (13Durante W. Liao L. Iftikhar I. Cheng K. Shafer A.I. J. Biol. Chem. 1996; 271: 11838-11843Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). In addition to transcellular transport, l-ornithine can be obtained from intracellular sources by endogenous synthesis. In this respect, the basic amino acid l-arginine, which enters cells via the same CATs as l-ornithine, is metabolized tol-ornithine and urea by arginase (27Barbul A. J. Parenter. Enteral Nutr. 1986; 10: 227-238Crossref PubMed Scopus (456) Google Scholar). This enzyme is found in a high concentration in the liver and has recently been identified in vascular cells (28Wu G. Meininger C. Am. J. Physiol. 1995; 269: H1312-H1318Crossref PubMed Google Scholar, 29Buga G.M. Singh R. Pervin S Rogers N.E. Schmitz D.A. Jenkinson C.P. Cederbaum S.D. Ignarro L.J. Am. J. Physiol. 1996; 271: H1988-H1998PubMed Google Scholar). Presently, little is known about the regulation of arginase activity in vascular SMC. Because lyso-PC stimulates SMC proliferation and because polyamines play a critical role in mediating cell growth, the present study was designed to determine whether lyso-PC regulates polyamine synthesis. We now report that lyso-PC coordinately induces the gene expression of CAT proteins and ODC, resulting in markedly increased production of polyamines by vascular SMC. In addition, lyso-PC promotes the intracellular metabolism of l-arginine to polyamines by stimulating arginase activity. These lyso-PC-induced actions that promote SMC proliferation are amplified by lyso-PC inhibition of the synthesis of antiproliferative NO by inhibition of iNOS protein expression. Fetal calf serum, sodium dodecyl sulfate, EDTA,l-arginine, l-ornithine, trichloroacetic acid, penicillin, streptomycin, elastase, collagenase, aprotonin, trypan blue, pyridoxal 5-phosphate, ammonium hydroxide, chloroform, formamide, methanol, Triton X-100, Tris, Tes, HEPES, ninhydrin spray, and TLC plates (Silica Gel 25) were purchased from Sigma. Lyso-PC (palmitoyl, C16:0) and PC (dipalmitoyl) were obtained from Avanti Polar Lipids (Alabaster, AL). l-NOHA was from Alexis Corporation (San Diego). Minimum essential medium was from ICN (Costa Mesa, CA). Leupeptin and MTT were from Boehringer Mannheim. Guanidine isothiocyanate and CsCl were from Life Technologies, Inc. Dithiothreitol and the Bradford protein assay were from Bio-Rad. Ribonuclease A and T1 and GAPDH cDNA were from Ambion Inc. (Austin, TX). Bicinchoninic acid protein assay was from Pierce. GeneScreen Plus membranes were from NEN Life Science Products. Murine monoclonal antibody to iNOS was from Transduction Laboratories (Lexington, KY). PDGF antibody was from Upstate Biotechnology (Lake Placid, NY). DFMO was generously provided by Dr. Ekkhardt H. W. Bohme (Marion Merrill Dow Inc., Cincinnati, OH). l-[3H]Ornithine (55 Ci/mmol) and l-[3H]arginine (58 Ci/mmol) were from American Radiolabeled Chemicals (St. Louis).l-[1-14C]Ornithine (55 mCi/mmol),l-[guanido-14C]arginine (52 mCi/mmol), [α-32P]UTP (400 Ci/mmol), and chemoluminescence reagents were from Amersham Corp. Vascular SMC were isolated by elastase and collagenase digestion of rat thoracic aorta and characterized by morphological and immunological criteria (30Durante W. Schini V.B. Catovksy S. Kroll M.H. Vanhoutte P.M. Schafer A.I. Am. J. Physiol. 1993; 264: H617-H623Crossref PubMed Google Scholar). Cells were cultured serially in minimum essential medium containing Earle's salts, 5.6 mm glucose, 2 mml-glutamine, 20 mm Tes-NaOH, 20 mm HEPES-NaOH, 100 units/ml penicillin, and 100 units/ml streptomycin. Subcultured strains were used between passages 6 and 26. When cells reached confluence, the culture media were replaced with serum-free media containing bovine serum albumin (0.1%) for 24 h. Treatment of vascular SMC with lyso-PC was restricted to those concentrations that did not affect cell viability, as determined by trypan blue exclusion (30Durante W. Schini V.B. Catovksy S. Kroll M.H. Vanhoutte P.M. Schafer A.I. Am. J. Physiol. 1993; 264: H617-H623Crossref PubMed Google Scholar) and by the mitochondria-dependent reduction of MTT to formazan (31Mosmann T. J. Immunol. Methods. 1983; 655: 55-63Crossref Scopus (45846) Google Scholar). Cationic amino acid transport was determined by measuring the influx of radiolabeledl-ornithine or l-arginine into SMC (21Durante W. Liao L. Schafer A.I. Am. J. Physiol. 1995; 268: H1158-H1164PubMed Google Scholar). Similar results were obtained with either basic amino acid. Cells were washed with HEPES buffer (140 mm choline chloride, 5.0 mm KCl, 1.0 mm MgCl2, 0.9 mm CaCl2, 5.6 mmd-glucose, and 25 mm HEPES, pH 7.4) and then incubated for 45 s in HEPES buffer containingl-[3H]ornithine orl-[3H]arginine (50 μm; 1 μCi). Transport activity was terminated by aspirating the media and rapidly washing the cells with ice-cold HEPES buffer. Cells were then solubilized by the addition of 0.2% sodium dodecyl sulfate in 0.2n NaOH, and a portion of the extract was collected for liquid scintillation counting. The remaining extract was used for the determination of protein concentration utilizing the bicinchoninic acid method with serum albumin as the standard. SMC were harvested in ice-cold Tris buffer (20 mm Tris, 0.1 mm EDTA, 2 mmdithiothreitol, and 0.1 mm pyridoxal 5-phosphate, pH 7.4), sonicated, and centrifuged at 14,000 × g for 20 min at 4 °C. The supernatant (soluble fraction) was collected, and ODC activity was determined by measuring the release of14CO2 froml-[1-14C]ornithine, as described previously (32Russell D.H. Snyder S.H. Mol. Pharmacol. 1969; 5: 253-262PubMed Google Scholar). Protein concentration was determined by the Bradford assay using γ-globulin as the standard, and enzymatic activity was expressed in pmol of CO2/mg of protein/h. Polyamine formation was determined by incubating SMC with l-[3H]ornithine orl-[3H]arginine and monitoring the intracellular formation of radiolabeled putrescine, as described previously (13Durante W. Liao L. Iftikhar I. Cheng K. Shafer A.I. J. Biol. Chem. 1996; 271: 11838-11843Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). SMC were incubated withl-[3H]ornithine orl-[3H]arginine (20 μCi/mmol) for 24 h and the reactions stopped by removing the radiolabel-containing media and washing the cells with ice-cold phosphate-buffered saline, pH 7.4. Cells were solubilized in Tris buffer (20 mm, pH 7.4) containing Triton X-100 (0.01%), and aliquots of the supernatant were spotted onto TLC plates and developed in the solvent system chloroform/methanol/ammonium hydroxide/water (1:4:2:1, v/v/v). After drying, putrescine was detected by ninhydrin spray, and [3H]putrescine was identified by co-chromatography with unlabeled putrescine, scraped, and quantified by liquid scintillation counting. Arginase activity was determined by monitoring the formation of [14C]urea froml-[guanido-14C]larginine (33Russell A.S. Ruegg U.T. J. Immunol. Methods. 1980; 32: 375-382Crossref PubMed Scopus (20) Google Scholar). SMC were lysed for 30 min in Tris buffer (10 mm, pH 7.4) containing Triton X-100 (0.4%), leupeptin (10 mg/ml), and aprotonin (10 mg/ml). Samples were centrifuged at 14,000 ×g for 10 min at 4 °C, and an aliquot of the supernatant was added to an equal volume of Tris buffer (10 mm, pH 7.4) containing MnCl2 (10 mm). Arginase was then activated by heating for 10 min at 56 °C and the arginase reaction initiated by adding Tris buffer (10 mm, pH 9.6) containingl-arginine (10 mm) and l-[guanido-14C]larginine (0.25 Ci). Samples were incubated at 37 °C for 20 min and reactions terminated by adding ice-cold sodium acetate (250 mm, pH 4.5) containing urea (100 mm). [14C]Urea was separated from basic amino acids by adding a continuously stirred suspension of Dowex resin (50W-X8 100–200 mesh; 1 g/ml water) to the samples. Samples were shaken, centrifuged at 1,000 × gfor 5 min, and an aliquot was collected for scintillation counting. Arginase activity was expressed in μmol of urea/mg of protein/h. Total cellular RNA was obtained by the guanidine isothiocyanate/CsCl procedure and RNA concentration determined by absorbance spectrophotometry at 260 nm (34Chirgwin J.M. Przbyla A.E. MacDonald R.J. Rutter W.J. Biochemistry. 1979; 18: 5294-5299Crossref PubMed Scopus (16648) Google Scholar). CAT mRNA levels were determined by solution hybridization/ribonuclease protection analysis; ODC mRNA levels were determined by Northern blotting (13Durante W. Liao L. Iftikhar I. Cheng K. Shafer A.I. J. Biol. Chem. 1996; 271: 11838-11843Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 35Durante W. Liao L. Schafer A.I. Proc. Assoc. Am. Phys. 1996; 108: 356-361PubMed Google Scholar, 36Gilmour S.K. Avdalovic N. Madara T. O'Brien T.G. J. Biol. Chem. 1985; 260: 16439-16444Abstract Full Text PDF PubMed Google Scholar). For both ribonuclease protection assays and Northern blotting, relative mRNA levels were quantified by scanning densitometry (LKB 2222-020 Ultrascan XL laser densitometer, Bromma, Sweden) and normalized with respect to GAPDH mRNA. The expression of iNOS by SMC was determined by measuring NO release and by monitoring iNOS protein levels. NO synthesis was assessed by measuring the extracellular release of nitrite, the stable oxidation product of NO (37Marletta M.A. Yoon P.S. Iyengar R. Leaf C.D. Wishnok J.S. Biochemistry. 1988; 27: 8706-8711Crossref PubMed Scopus (1418) Google Scholar), with the Griess reagent (38Green L.C. Wagner D.A. Glogowsky J. Skipper P.L. Wishnok J.S. Tannenbaum S.R. Anal. Biochem. 1982; 126: 131-138Crossref PubMed Scopus (10733) Google Scholar). iNOS protein levels were determined by Western blotting using anti-mouse iNOS IgG, as described previously (39Durante W. Liao L. Iftikhar I. O'Brien W.E. Schafer A.I. Circ. Res. 1996; 78: 1075-1082Crossref PubMed Scopus (64) Google Scholar,40Durante W. Cheng K. Sunahara F.A. Schafer A.I. Biochem. J. 1995; 308: 231-236Crossref PubMed Scopus (41) Google Scholar). Results are expressed as the means ± S.E. Statistical analysis was performed with the use of Student's two-tailed t test and an analysis of variance when more than two treatments were compared; p values < 0.05 were considered to be statistically significant. Treatment of vascular SMC with lyso-PC stimulated the transport ofl-ornithine and l-arginine in a concentration-dependent manner (Fig.1). In contrast, PC had no effect on cationic amino acid transport (Fig. 1). Time course studies demonstrated that lyso-PC (100 μm) had a biphasic effect on cationic amino acid transport (Fig.2). Initially, lyso-PC inhibited the transport of basic amino acids, but by 6 h of lyso-PC treatment a significant rise in transport was observed; this was increased further after 24 h of treatment. Incubation of SMC with a neutralizing antibody directed against PDGF had no effect on lyso-PC-stimulated l-ornithine transport but completely prevented the PDGF-mediated increase in uptake (data not shown).Figure 2Time course of lyso-PC-regulated cationic amino acid transport in vascular SMC. Specific transport of 50 μml-[3H]ornithine orl-[3H]arginine was measured in HEPES buffer after preincubation with lyso-PC (100 μm) for the indicated times. Results are means ± S.E. of three separate experiments, each performed in triplicate. * indicates a statistically significant effect of lyso-PC treatment.View Large Image Figure ViewerDownload Hi-res image Download (PPT) In subsequent kinetic studies, saturable uptake of radiolabeledl-ornithine (5–500 μm) was measured. As evident from a representative Eadie-Hofstee plot (Fig.3), high affinity uptake ofl-ornithine by vascular SMC was mediated by a single carrier. Data from several experiments (n = 5) indicated that this transporter had a Michaelis constant (K m ) of 128.3 ± 13.1 μm and a maximum transport velocity (V max) of 770 ± 77 pmol/mg of protein/45 s. Pretreatment of vascular SMC with lyso-PC (100 μm) for 24 h significantly increased both theK m (216.6 ± 14.5 μm;p < 0.05) and V max (3,206 ± 195 pmol/mg of protein/45 s; p < 0.05) of thel-ornithine transporter. The increase inV max of cationic amino transport by lyso-PC was completely abolished with actinomycin D (2 μg/ml) (data not shown). Treatment of vascular SMC with lyso-PC (100 μm) rapidly induced the expression of the mRNA of both cationic amino acid transporters, CAT-1 and CAT-2 (Fig. 4). Both CAT transcripts peaked 2 h after exposure to lyso-PC; however, the increase in CAT-2 message (≈20-fold) was much greater than that of CAT-1 (≈3-fold) (Fig. 4). The elevated levels of CAT mRNA decayed rapidly, but messages for CATs reappeared again at 24 h at levels comparable to those observed at 2 h (Fig.4). Incubation of vascular SMC with lyso-PC also induced ODC activity. Significant increases in enzyme activity were evident 4 h after lyso-PC (100 μm) addition, reached maximum activity at 8 h (≈20-fold), and then declined to near basal levels by 24 h (Fig. 5 A). Increases in ODC activity were dependent on the concentration of lyso-PC (Fig.5 B) and were blocked by actinomycin D (data not shown). In contrast, PC failed to stimulate ODC activity (data not shown). SMC expressed two faint ODC transcripts of approximately 2.6 and 2.2 kb (Fig. 6). Treatment of SMC with lyso-PC resulted in a concentration-dependent increase in ODC message with proportional increases (≈12-fold) in the two mRNA species (Fig. 6).Figure 6Effect of lyso-PC on the expression of ODC mRNA in vascular SMC. Panel A, Northern blot of ODC (2.6- and 2.2-kb transcripts) and GAPDH (1.4 kb) mRNA after the treatment of SMC with lyso-PC (30–100 μm) for 8 h.Panel B, relative ODC mRNA (2.6 kb, open bars; 2.2 kb, solid bars) levels derived from laser densitometric analysis of ODC transcripts expressed after lyso-PC treatment compared with control untreated (C) SMC. Data shown are representative of two independent experiments.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Treatment of vascular SMC with lyso-PC increased the capacity of SMC to generate the polyamine putrescine from extracellularl-ornithine in a concentration-dependent manner (Fig. 7 A). The stimulatory effect of lyso-PC on putrescine synthesis was inhibited by the cationic amino acid transport inhibitorN G-methyl-l-arginine (21Durante W. Liao L. Schafer A.I. Am. J. Physiol. 1995; 268: H1158-H1164PubMed Google Scholar) and by the selective ODC inhibitor DFMO (15Pegg A.E. Cancer Res. 1988; 48: 759-774PubMed Google Scholar) (Fig. 7 B). Vascular SMC also expressed constitutive arginase activity (1.6 ± 0.2 μmol of urea/mg of protein/h, n = 4) which was increased by lyso-PC in a concentration-dependent manner (Fig. 8 A). In addition, lyso-PC increased the capacity of SMC to generate putrescine from extracellular l-arginine (Fig. 8 B). The latter experiments were based on the rationale that l-arginine must be converted to l-ornithine by arginase to be metabolized to putrescine by the action of ODC. Therefore, stimulation of arginase by lyso-PC would result in increased synthesis of [3H]putrescine froml-[3H]arginine. The stimulatory effect of lyso-PC on putrescine synthesis was inhibited by the arginase inhibitorl-NOHA (41Daghigh F. Fukuto J.M. Ash D.E. Biochem. Biophys. Res. Commun. 1994; 202: 174-180Crossref PubMed Scopus (161) Google Scholar, 42Hecker M. Nematollahi H. Hey C. Busse R. Racke K. FEBS Lett. 1995; 359 (154): 251Crossref PubMed Scopus (112) Google Scholar) and by the ODC inhibitor DFMO (Fig.8 B). Finally, incubating SMC with interleukin-1β (5 ng/ml) for 24 h stimulated the accumulation of nitrite in the incubation medium and induced the expression of iNOS protein (Fig.9). The addition of lyso-PC (100 μm) to SMC inhibited the interleukin-1β-stimulated production of the NO oxidation product, nitrite, in a concentration-dependent manner and reduced markedly the cytokine-induced rise in iNOS protein (Fig. 9). In the absence of interleukin-1β, lyso-PC had no effect on SMC NO production or iNOS protein levels (Fig. 9). The present study demonstrates that lyso-PC stimulates polyamine synthesis in vascular SMC by modulating the expression of the genes that regulate the transport and metabolism of cationic amino acids (see Fig. 10). In particular, lyso-PC increases the transcellular transport of basic amino acids and the intracellular metabolism of l-ornithine to polyamines by stimulating the expression of the genes for both CAT and ODC. In addition, lyso-PC directs the intracellular metabolism ofl-arginine to polyamines by stimulating arginase activity and by blocking iNOS. These effects are specific for the lysophospholipid because PC has no effect on cationic amino acid transport or metabolism. The capacity of lyso-PC to augment the transport of basic amino acids and direct their metabolism to growth-stimulatory polyamines (and away from growth-inhibitory NO) may contribute to the proliferative actions of lyso-PC. Treatment of vascular SMC with lyso-PC stimulates the transport of cationic amino acids in both a time- and concentration-dependent manner. Kinetic experiments indicate that high affinity (K m ≈ 130 μm) basic amino acid transport is mediated by a single carrier system and that lyso-PC increases both theV max and K m of this transport system. These kinetic data suggest that the lyso-PC-induced decrease in cationic amino acid uptake observed at early time points likely arises from a lyso-PC-mediated decrease in affinity of the transporter. In contrast, the increase in basic amino acid transport observed at later time points may result from the de novo induction of transport protein. Studies in our laboratory and others have demonstrated that high affinity transport of cationic amino acids by vascular SMC is mediated by CAT-1 and CAT-2 (13Durante W. Liao L. Iftikhar I. Cheng K. Shafer A.I. J. Biol. Chem. 1996; 271: 11838-11843Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 43Low B.C. Grigor M.R. J. Biol. Chem. 1995; 270: 27577-27583Abstract Full Text Full Text PDF PubMed Scopus (52) Google Scholar). Consistent with this, our current study demonstrates that lyso-PC stimulates CAT-1 and CAT-2 mRNA expression. Although the relative contribution of these CAT proteins to the overall activity of the system y+carrier is difficult to determine because of their similar kinetic properties, the much greater increase in CAT-2 mRNA compared with CAT-1 suggests that CAT-2B mediates most of the lyso-PC-mediated increase in l-ornithine transport. Interestingly, whereas CAT mRNA expression is elevated during the initial 2 h after lyso-PC treatment, transport activity is increased several hours later when CAT transcripts have decayed to near basal levels. This dissociation between CAT message and transport activity may reflect the time required for the translation, post-translational modification, and eventual insertion of the CAT protein into the plasma membrane to yield a functional transporter. The co-expression of both CAT-1 and CAT-2 mRNA in vascular SMC after lyso-PC treatment is also observed after the administration of PDGF or angiotensin, but it contrasts with the selective expression of CAT-2 by inflammatory cytokines (13Durante W. Liao L. Iftikhar I. Cheng K. Shafer A.I. J. Biol. Chem. 1996; 271: 11838-11843Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 43Low B.C. Grigor M.R. J. Biol. Chem. 1995; 270: 27577-27583Abstract Full Text Full Text PDF PubMed Scopus (52) Google Scholar, 44Gill D.J. Low B.C. Grigor M.R. J. Biol. Chem. 1996; 271: 11280-11283Abstract Full Text Full Text PDF PubMed Scopus (66) Google Scholar). Interestingly, lyso-PC induces PDGF synthesis from vascular cells (7Kume N. Gimbrone Jr., M.A. J. Clin. Invest. 1994; 93: 907-911Crossref PubMed Scopus (298) Google Scholar), raising the possibility that the lyso-PC effect is secondary to PDGF release. However, neutralizing antibodies to PDGF fail to modulate lyso-PC-mediated increases in basic amino acid uptake. It is possible that SMC-derived PDGF exerts its effect in an intracrine manner, which would be unaffected by neutralizing antibodies. The ability of lyso-PC to stimulate CAT gene expression directly and to evoke the release of secondary autocrine mediators may account for the biphasic temporal expression of CAT transcripts. In addition to stimulating l-ornithine transport, lyso-PC stimulates the metabolism of intracellular l-ornithine to polyamines in vascular SMC. The lyso-PC-mediated increase in ODC activity is paralleled by an increase in ODC mRNA, suggesting that lyso-PC stimulates ODC gene transcription. The inhibition of lyso-PC-stimulated ODC activity by the transcriptional inhibitor actinomycin D is consistent with this notion. The presence of two ODC mRNA species in vascular SMC is also in agreement with previous studies utilizing other cell types and inducing stimuli (36Gilmour S.K. Avdalovic N. Madara T. O'Brien T.G. J. Biol. Chem. 1985; 260: 16439-16444Abstract Full Text PDF PubMed Google Scholar, 45Berger F.G. Szymanski P. Read E. Watson G. J. Biol. Chem. 1984; 259: 7941-7946Abstract Full Text PDF PubMed Google Scholar). The two ODC mRNA species arise from the alternative use of two different polyadenylation signals (46Hickok N.J. Seppanen P.J. Kontula K.K. Janne P.A. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 594-598Crossref PubMed Scopus (68) Google Scholar, 47Wen L. Huang J.-K. Blackshear P.J. J. Biol. Chem. 1989; 264: 9016-9021Abstract Full Text PDF PubMed Google Scholar). The transport and metabolism of l-ornithine appear to be closely coupled after lyso-PC administration. This is reflected by the delayed, parallel concentration-dependent increase in CAT and ODC activities. The co-induction of these two proteins by lyso-PC may provide a mechanism by which increased levels of substrate (l-ornithine) are provided to SMC during activation of the ODC enzyme. In this respect, treatment of vascular SMC with lyso-PC is associated with a prominent increase in the capacity of SMC to generate putrescine. This lyso-PC-mediated effect is blocked by the cationic amino acid transport inhibitorN G-methyl-l-arginine and by the selective ODC inhibitor DFMO, indicating that both the transcellular transport of l-ornithine and ODC activity are limiting factors that regulate the capacity of lyso-PC to generate polyamines in vascular SMC. Interestingly, whereas lyso-PC results in a transient elevation in ODC activity which returns to basal levels after 24 h of lyso-PC exposure, cationic amino acid transport activity increases progressively during this time. These findings indicate thatl-ornithine uptake is dissociated from polyamine synthesis at later time points. The elevated rate of transport at this time may function to provide the necessary amino acids required for the synthesis of new proteins during cell growth. Because lyso-PC stimulates the transcellular transport ofl-arginine as well as l-ornithine into SMC, the effect of lyso-PC on intracellular l-arginine metabolism was also investigated. We found that vascular SMC possess substantial arginase activity and that lyso-PC increases this activity. This finding complements recent studies demonstrating constitutive arginase activity in endothelial cells (28Wu G. Meininger C. Am. J. Physiol. 1995; 269: H1312-H1318Crossref PubMed Google Scholar, 29Buga G.M. Singh R. Pervin S Rogers N.E. Schmitz D.A. Jenkinson C.P. Cederbaum S.D. Ignarro L.J. Am. J. Physiol. 1996; 271: H1988-H1998PubMed Google Scholar). Although the physiological role of arginase activity in vascular cells is unknown, we suggest that arginase may function to shunt l-arginine tol-ornithine metabolism to generate biologically relevant polyamines. In support of this proposal, we found that lyso-PC increases the capacity of SMC to generate putrescine froml-arginine and that this lyso-PC effect is blocked by the arginase inhibitor l-NOHA. The ability of lyso-PC to induce coordinately the transcellular transport and the intracellular synthesis of l-ornithine may function to maximize the cellular capacity for polyamine biosynthesis. In vascular SMC l-arginine is also metabolized to NO andl-citrulline by iNOS (48Busse R. Mulsch A. FEBS Lett. 1990; 275: 87-90Crossref PubMed Scopus (666) Google Scholar). NO is an important antiatherogenic molecule. In addition to being a potent vasodilator, it inhibits platelet aggregation, vascular SMC proliferation, and monocyte adherence, all of which are key contributors in the development of atherosclerosis (49Gruetter C.A. Barry B.K. McNamara D.B. Gruetter D.Y. Kadowitz P.J. Ignarro L.J. J. Cyclic Nucleotide Res. 1979; 5: 211-224PubMed Google Scholar, 50Mellion B.T. Ignarro L.J. Ohlstein L.J. Ponotocorvo E.G. Hyman A.L. Kadowitz P.J. Blood. 1981; 57: 946-955Crossref PubMed Google Scholar, 51Garg U.C. Hassid A. J. Clin. Invest. 1990; 83: 1018-1031Google Scholar, 52Bath P.M.W. Hassal D.G. Gladwin A.-M. Palmer R.M.J. Martin J.F. Arterioscler. Thromb. 1991; 11: 254-260Crossref PubMed Scopus (300) Google Scholar). In the present study we found that lyso-PC attenuates cytokine-stimulated SMC NO synthesis by inhibiting iNOS protein expression. In contrast, an earlier study demonstrated that lyso-PC stimulates the transcriptional activation of the constitutive endothelial NOS gene (53Zembowicz A. Tang J. Wu K.K. J. Biol. Chem. 1995; 270: 17006-17010Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar). These results indicate that lyso-PC has divergent isoform-specific regulatory effects on NOS gene expression. The ability of lyso-PC to shunt the metabolism ofl-arginine from the iNOS to the arginase pathway in vascular SMC may serve to promote further the mitogenic and atherogenic effects of lyso-PC. The concentration of lyso-PC required to regulate cationic amino acid transport and metabolism in vascular SMC is similar to the level needed to induce gene expression of other proteins in vascular cells (6Kume N. Cybulsky M.I. Gimbrone Jr., M.A. J. Clin. Invest. 1992; 90: 1138-1144Crossref PubMed Scopus (723) Google Scholar, 7Kume N. Gimbrone Jr., M.A. J. Clin. Invest. 1994; 93: 907-911Crossref PubMed Scopus (298) Google Scholar,53Zembowicz A. Tang J. Wu K.K. J. Biol. Chem. 1995; 270: 17006-17010Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar). Although this concentration is higher than the level of lyso-PC present in oxidized low density lipoprotein (≈10 μm) (8Chai Y.-C. Howe P.H. DiCorleto P.E. Chisolm G.M. J. Biol. Chem. 1996; 271: 17791-17797Abstract Full Text Full Text PDF PubMed Scopus (138) Google Scholar, 54Yokoyama M. Hirata K. Miyake R. Akita H. Ishikawa Y. Fukuzaki H. Biochem. Biophys. Res. Commun. 1990; 168: 301-308Crossref PubMed Scopus (170) Google Scholar, 55Locher R. Weisser B. Mengden T. Brunner C. Vetter W. Biochem. Biophys. Res. Commun. 1992; 183: 156-162Crossref PubMed Scopus (27) Google Scholar), the response of SMC to lyso-PC may be physiologically relevant because cells can generate additional lyso-PC by the action of phospholipase A2 on membrane PC (56Vadas P. Prudzanski W. Lab. Invest. 1986; 55: 391-404PubMed Google Scholar). Moreover, the actual concentration of free lyso-PC in our study is much lower than the reported concentration because the experiments were performed in the presence of albumin, which has a high affinity for lysophospholipids (57Ulrich K.H. Pharmacol. Rev. 1981; 33: 17-54PubMed Google Scholar). In conclusion, these studies demonstrate that lyso-PC stimulates the transport of cationic amino acids by inducing the expression of the genes for CAT-1 and CAT-2 and increases l-ornithine metabolism by inducing ODC activity. In addition, lyso-PC redirects the metabolism of l-arginine from the formation of antiproliferative NO to the synthesis of growth-stimulatory polyamines. As shown in the model in Fig. 10, these multiple sites of action of lyso-PC found in this study appear to be coordinately directed toward promoting the proliferative capacity of vascular SMC. The actions of lyso-PC to up-regulate basic amino acid transport and direct their metabolism to polyamines may contribute to SMC proliferation and atherosclerotic lesion formation." @default.
• W2016647946 created "2016-06-24" @default.
• W2016647946 creator A5000979448 @default.
• W2016647946 creator A5026743154 @default.
• W2016647946 creator A5063583165 @default.
• W2016647946 creator A5070064210 @default.
• W2016647946 date "1997-11-01" @default.
• W2016647946 modified "2023-10-11" @default.
• W2016647946 title "Lysophosphatidylcholine Regulates Cationic Amino Acid Transport and Metabolism in Vascular Smooth Muscle Cells" @default.
• W2016647946 cites W127742586 @default.
• W2016647946 cites W1529376098 @default.
• W2016647946 cites W1544564280 @default.
• W2016647946 cites W1554160442 @default.
• W2016647946 cites W1575097947 @default.
• W2016647946 cites W1592312760 @default.
• W2016647946 cites W1607148144 @default.
• W2016647946 cites W16937459 @default.
• W2016647946 cites W1965264787 @default.
• W2016647946 cites W1975982125 @default.
• W2016647946 cites W1976211275 @default.
• W2016647946 cites W1990802251 @default.
• W2016647946 cites W1994193282 @default.
• W2016647946 cites W1997946388 @default.
• W2016647946 cites W2011992952 @default.
• W2016647946 cites W2028272667 @default.
• W2016647946 cites W2034709023 @default.
• W2016647946 cites W2035177724 @default.
• W2016647946 cites W2044263892 @default.
• W2016647946 cites W2045147217 @default.
• W2016647946 cites W2048849367 @default.
• W2016647946 cites W2053871412 @default.
• W2016647946 cites W2054390123 @default.
• W2016647946 cites W2058350997 @default.
• W2016647946 cites W2060333964 @default.
• W2016647946 cites W2060355646 @default.
• W2016647946 cites W2064762100 @default.
• W2016647946 cites W2073861766 @default.
• W2016647946 cites W2075451343 @default.
• W2016647946 cites W2078852391 @default.
• W2016647946 cites W2079076761 @default.
• W2016647946 cites W2091732701 @default.
• W2016647946 cites W2093037006 @default.
• W2016647946 cites W2093918191 @default.
• W2016647946 cites W2099992849 @default.
• W2016647946 cites W2114918609 @default.
• W2016647946 cites W2130075870 @default.
• W2016647946 cites W2135038548 @default.
• W2016647946 cites W2171371444 @default.
• W2016647946 cites W2326202471 @default.
• W2016647946 cites W2336712874 @default.
• W2016647946 cites W2396712276 @default.
• W2016647946 cites W2418871452 @default.
• W2016647946 cites W2767031288 @default.
• W2016647946 cites W3022864527 @default.
• W2016647946 cites W4238270754 @default.
• W2016647946 doi "https://doi.org/10.1074/jbc.272.48.30154" @default.
• W2016647946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9374496" @default.
• W2016647946 hasPublicationYear "1997" @default.
• W2016647946 type Work @default.
• W2016647946 sameAs 2016647946 @default.
• W2016647946 citedByCount "44" @default.
• W2016647946 countsByYear W20166479462012 @default.
• W2016647946 countsByYear W20166479462013 @default.
• W2016647946 countsByYear W20166479462014 @default.
• W2016647946 countsByYear W20166479462018 @default.
• W2016647946 countsByYear W20166479462021 @default.
• W2016647946 crossrefType "journal-article" @default.
• W2016647946 hasAuthorship W2016647946A5000979448 @default.
• W2016647946 hasAuthorship W2016647946A5026743154 @default.
• W2016647946 hasAuthorship W2016647946A5063583165 @default.
• W2016647946 hasAuthorship W2016647946A5070064210 @default.
• W2016647946 hasBestOaLocation W20166479461 @default.
• W2016647946 hasConcept C134018914 @default.
• W2016647946 hasConcept C178790620 @default.
• W2016647946 hasConcept C183882617 @default.
• W2016647946 hasConcept C185592680 @default.
• W2016647946 hasConcept C2776330855 @default.
• W2016647946 hasConcept C2778596009 @default.
• W2016647946 hasConcept C2778918659 @default.
• W2016647946 hasConcept C2779395532 @default.
• W2016647946 hasConcept C2992686903 @default.
• W2016647946 hasConcept C41625074 @default.
• W2016647946 hasConcept C515207424 @default.
• W2016647946 hasConcept C55493867 @default.
• W2016647946 hasConcept C62231903 @default.
• W2016647946 hasConcept C86803240 @default.
• W2016647946 hasConcept C95444343 @default.
• W2016647946 hasConceptScore W2016647946C134018914 @default.
• W2016647946 hasConceptScore W2016647946C178790620 @default.
• W2016647946 hasConceptScore W2016647946C183882617 @default.
• W2016647946 hasConceptScore W2016647946C185592680 @default.
• W2016647946 hasConceptScore W2016647946C2776330855 @default.
• W2016647946 hasConceptScore W2016647946C2778596009 @default.
• W2016647946 hasConceptScore W2016647946C2778918659 @default.
• W2016647946 hasConceptScore W2016647946C2779395532 @default.
• W2016647946 hasConceptScore W2016647946C2992686903 @default.
• W2016647946 hasConceptScore W2016647946C41625074 @default.
• W2016647946 hasConceptScore W2016647946C515207424 @default.

• next